<DOC>
	<DOCNO>NCT00290979</DOCNO>
	<brief_summary>- To evaluate non-inferiority efficacy HMR1964 compare Insulin lispro term change HbA1C baseline endpoint . - To compare safety HMR1964 insulin lispro .</brief_summary>
	<brief_title>Efficacy Safety Insulin Glulisine Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>- To compare HMR1964 insulin lispro term change HbA1C baseline week 12 week 28 ; consecutive change HbA1C every 4 week , blood glucose parameter , symptomatic hypoglycemia insulin dos ( rapid-acting , basal total ) . - To collect 6-month safety data HMR1964 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Men woman type 1 diabetes mellitus , HbA1C range &gt; =6.0 = &lt; 11.0 % , basalbolus insulin regimen . They must least 1 year continuous insulin treatment date inform consent . Subjects received oral hypoglycemic agent insulin within 4 week prior inform consent Subjects receive oral intravenous corticosteroid within 4 week prior inform consent Subjects treat another investigational product within 12 week prior inform consent Subjects likelihood require concomitant treatment study period drug permit study protocol Subjects clinically relevant cardiovascular , hepatic , neurologic , endocrine , active cancer , serious complication systemic disease make implementation protocol interpretation study result difficult Subjects undergone pancreatectomy pancreas/islet cell transplant Night shift worker Subjects unlikely comply study protocol , e.g. , inability periodic return followup visit , unlikelihood complete study Subjects previously treat HMR1964 Subjects pregnant , breast feeding wish become pregnant study period Female subject possibly pregnant [ female subject reproductive potential serum human chorionic gonadotropin ( hCG ) level &gt; 0.7 mIU/mL determine central laboratory , SRL Medisearch Inc. , screen phase ] Subjects diabetic retinopathy receive surgical treatment ( laser photocoagulation vitrectomy ) within 24 week prior inform consent , expect surgical treatment study period Subjects history alcohol abuse Subjects hypersensitivity insulin preparation Subjects impair hepatic function ( SGOT SGPT Â³= &lt; 80 IU/L determine central laboratory , SRL Medisearch Inc. , screen phase ) impair renal function ( serum creatinine = &lt; 2.0 mg/dL determine central laboratory , SRL Medisearch Inc. , screen phase ) Subjects judged investigator subinvestigator inappropriate subject study reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>HMR1964 , insulin glulisine , Diabetes Mellitus , Type 1</keyword>
</DOC>